<DOC>
	<DOCNO>NCT03015324</DOCNO>
	<brief_summary>Hydroxychloroquine administer outpatient basis within 12 week primary surgery follow adjuvant chemotherapy /or radiation therapy ( need ) . Hydroxychloroquine administer orally dose 400 mg daily 90 day . Subjects receive HCQ every day .</brief_summary>
	<brief_title>Biological Effects Agent PAR-4 Levels With Resected Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Hydroxychloroquine</mesh_term>
	<criteria>Histologically confirm solid tumor surgically resect Have complete plan adjuvant therapy plan adjuvant therapy Age ≥18 year ECOG performance status ≤1 ( Karnofsky ≥80 % ) Patients must able ingest oral medication ( crush administer via PEG tube acceptable ) Patients must normal organ marrow function define : absolute neutrophil count ≥1,500/mcL platelets ≥100,000/mcL total bilirubin Less 1.5 x ULN AST ( SGOT ) /ALT ( SGPT ) ≤2.5 × institutional upper limit normal creatinine within normal institutional limit OR creatinine clearance ≥50 mL/min/1.73 m2 patient creatinine level institutional normal Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . Men treat enrol protocol must also agree use adequate contraception prior study , duration study participation , four month completion hydroxychloroquine administration . Ability understand willingness sign write informed consent document . Approval hydroxychloroquine treatment eye doctor , base screen eye exam . Patients metastatic cancer and/or cancer amenable surgery . Patients significant malabsorption determine treat physician . Patients receive investigational agent . Patients know brain metastasis exclude clinical trial poor prognosis often develop progressive neurologic dysfunction would confound evaluation neurologic adverse event . Patients primary brain tumor amenable surgery allow protocol . History allergic reaction attribute compound similar chemical biologic composition hydroxychloroquine receive HCQ past six month . Patients uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Pregnant woman exclude study . HIVpositive patient combination antiretroviral therapy ineligible Patients enzymeinducing antiepileptic medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>